Meloxicam oral suspension ( DrugBank: Meloxicam )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 2 |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00034853 (ClinicalTrials.gov) | December 2000 | 2/5/2002 | Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) | A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis | Arthritis, Juvenile Rheumatoid | Drug: meloxicam oral suspension;Drug: naproxen oral suspension | Boehringer Ingelheim | NULL | Completed | 2 Years | 17 Years | Both | 180 | Phase 3 | United States;Brazil;Mexico;Ukraine;Argentina |
| 2 | NCT00279747 (ClinicalTrials.gov) | September 2000 | 19/1/2006 | A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) | A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis. | Arthritis, Juvenile Rheumatoid | Drug: meloxicam 0.25 mg/kg;Drug: meloxicam 0.125 mg/kg;Drug: naproxen 10 mg/kg | Boehringer Ingelheim | NULL | Completed | 2 Years | 16 Years | Both | 226 | Phase 3 | Austria;Belgium;France;Germany;Italy;Russian Federation;United Kingdom |